Randomized Comparison of Contrast Agents Gadopiclenol and Gadobutrol in the Workup of Incidental Renal and Adrenal Findings

Randomized, Single-Blind, Monocentric, Non-Inferiority Trial of Gadopiclenol (Vueway®) Contrast Agent Performance vs. Gadobutrol (Gadovist®) in the Workup of Incidental Renal and Adrenal Findings

The purpose of this study is to compare the effects of the contrast agent Gadopiclenol with those of the standard contrast agent Gadobutrol.

The main question of this study is :

Does gadopiclenol offer diagnostic properties that are equally effective as those of gadobutrol?

Participants will be:

• randomly assigned to one of two groups: the experimental group, which receives gadopiclenol, or the control group, which receives gadobutrol. Each participant is informed of their group allocation prior to the magnetic resonance imaging (MRI) scan.
• invited for a single MRI appointment lasting approximately 60 minutes

Inclusion Criteria:

• signed informed consent
• age ≥18 years
• compatibility with magnetic resonance imaging
• planned workup of kidney incidental finding or adrenal incidental findings (or both)
• body mass index (BMI) < 31 kg/m2

Exclusion Criteria:

• patients with implants that might affect imaging parameters in the region under investigation, as judged by the principal investigator
• vulnerable individuals
• claustrophobic individuals
• individuals that are cognitively impaired or unable to understand the language
• pregnant or breastfeeding patients